<DOC>
	<DOC>NCT00160563</DOC>
	<brief_summary>Prolongation of the EPAACâ„¢ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic children.</brief_summary>
	<brief_title>Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>Inclusion criteria which must be verified at the end of first 18months treatment (Visit 9) Having completed the previous 18month treatment period of the EPAAC trial NCT00152464</criteria>
	<gender>All</gender>
	<minimum_age>30 Months</minimum_age>
	<maximum_age>42 Months</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Pediatry</keyword>
	<keyword>EPAAC</keyword>
	<keyword>atopic Children</keyword>
	<keyword>prevention of asthma</keyword>
	<keyword>Levocetirizine</keyword>
	<keyword>Xyzal</keyword>
</DOC>